$36.7 Billion Worldwide Diabetes Devices Industry to 2027

September 16, 2020

“Diabetes Devices – Global Market Trajectory & Analytics”: Research and Markets bring years of research experience to the 6th edition of this report. The 180-page report presents concise insights into how the pandemic has impacted production and the buy-side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Global Diabetes Devices Market to Reach $36.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Diabetes Devices estimated at US$24.7 Billion in the year 2020, is projected to reach a revised size of US$36.7 Billion by 2027, growing at a CAGR of 5.8% over the period 2020-2027.

Monitoring and Diagnostic Devices, one of the segments analyzed in the report, is projected to record 5.8% CAGR and reach US$26.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Insulin Delivery Devices segment is readjusted to a revised 6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $6.7 Billion, While China is Forecast to Grow at 8.9% CAGR

The Diabetes Devices market in the U.S. is estimated at US$6.7 Billion in the year 2020. China, the world`s second-largest economy, is forecast to reach a projected market size of US$7.8 Billion by the year 2027 trailing a CAGR of 8.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.2% and 5.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Competitors identified in this market include, among others:

  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Medtronic PLC
  • Novo Nordisk A/S
  • Sanofi SA

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Global Competitor Market Shares
  • Diabetes Devices Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
  • Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

  • Total Companies Profiled: 42

Additional information can be found here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version